Allakos Inc
NASDAQ:ALLK

Watchlist Manager
Allakos Inc Logo
Allakos Inc
NASDAQ:ALLK
Watchlist
Price: 0.8766 USD -3.34% Market Closed
Market Cap: 78.3m USD
Have any thoughts about
Allakos Inc?
Write Note

Intrinsic Value

ALLK's intrinsic value estimate is unreliable because it is based only on its DCF value and doesn't use a relative valuation using multiples.

The intrinsic value of one ALLK stock under the Base Case scenario is 1.0378 USD. Compared to the current market price of 0.8766 USD, Allakos Inc is Undervalued by 16%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

ALLK Intrinsic Value
1.0378 USD
Undervaluation 16%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Allakos Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for ALLK cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about ALLK?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Allakos Inc

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Allakos Inc

Provide an overview of the primary business activities
of Allakos Inc.

What unique competitive advantages
does Allakos Inc hold over its rivals?

What risks and challenges
does Allakos Inc face in the near future?

Has there been any significant insider trading activity
in Allakos Inc recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Allakos Inc.

Provide P/S
for Allakos Inc.

Provide P/E
for Allakos Inc.

Provide P/OCF
for Allakos Inc.

Provide P/FCFE
for Allakos Inc.

Provide P/B
for Allakos Inc.

Provide EV/S
for Allakos Inc.

Provide EV/GP
for Allakos Inc.

Provide EV/EBITDA
for Allakos Inc.

Provide EV/EBIT
for Allakos Inc.

Provide EV/OCF
for Allakos Inc.

Provide EV/FCFF
for Allakos Inc.

Provide EV/IC
for Allakos Inc.

Show me price targets
for Allakos Inc made by professional analysts.

What are the Revenue projections
for Allakos Inc?

How accurate were the past Revenue estimates
for Allakos Inc?

What are the Net Income projections
for Allakos Inc?

How accurate were the past Net Income estimates
for Allakos Inc?

What are the EPS projections
for Allakos Inc?

How accurate were the past EPS estimates
for Allakos Inc?

What are the EBIT projections
for Allakos Inc?

How accurate were the past EBIT estimates
for Allakos Inc?

Compare the revenue forecasts
for Allakos Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Allakos Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Allakos Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Allakos Inc compared to its peers.

Compare the P/E ratios
of Allakos Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Allakos Inc with its peers.

Analyze the financial leverage
of Allakos Inc compared to its main competitors.

Show all profitability ratios
for Allakos Inc.

Provide ROE
for Allakos Inc.

Provide ROA
for Allakos Inc.

Provide ROIC
for Allakos Inc.

Provide ROCE
for Allakos Inc.

Provide Gross Margin
for Allakos Inc.

Provide Operating Margin
for Allakos Inc.

Provide Net Margin
for Allakos Inc.

Provide FCF Margin
for Allakos Inc.

Show all solvency ratios
for Allakos Inc.

Provide D/E Ratio
for Allakos Inc.

Provide D/A Ratio
for Allakos Inc.

Provide Interest Coverage Ratio
for Allakos Inc.

Provide Altman Z-Score Ratio
for Allakos Inc.

Provide Quick Ratio
for Allakos Inc.

Provide Current Ratio
for Allakos Inc.

Provide Cash Ratio
for Allakos Inc.

What is the historical Revenue growth
over the last 5 years for Allakos Inc?

What is the historical Net Income growth
over the last 5 years for Allakos Inc?

What is the current Free Cash Flow
of Allakos Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Allakos Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Allakos Inc

Current Assets 97.2m
Cash & Short-Term Investments 92.7m
Other Current Assets 4.4m
Non-Current Assets 27.3m
PP&E 25.6m
Other Non-Current Assets 1.7m
Current Liabilities 16m
Accounts Payable 4m
Accrued Liabilities 11.4m
Other Current Liabilities 660k
Non-Current Liabilities 35.7m
Other Non-Current Liabilities 35.7m
Efficiency

Earnings Waterfall
Allakos Inc

Revenue
0 USD
Operating Expenses
-159.1m USD
Operating Income
-159.1m USD
Other Expenses
-19.7m USD
Net Income
-178.7m USD

Free Cash Flow Analysis
Allakos Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

ALLK Profitability Score
Profitability Due Diligence

Allakos Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

27/100
Profitability
Score

Allakos Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

ALLK Solvency Score
Solvency Due Diligence

Allakos Inc's solvency score is 57/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Long-Term Solvency
Low Altman Z-Score
57/100
Solvency
Score

Allakos Inc's solvency score is 57/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ALLK Price Targets Summary
Allakos Inc

Wall Street analysts forecast ALLK stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ALLK is 2.9376 USD with a low forecast of 1.01 USD and a high forecast of 7.35 USD.

Lowest
Price Target
1.01 USD
15% Upside
Average
Price Target
2.9376 USD
235% Upside
Highest
Price Target
7.35 USD
738% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for ALLK?

Click here to dive deeper.

Dividends

Allakos Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for ALLK is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

ALLK Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

ALLK News

Profile

Allakos Inc Logo
Allakos Inc

Country

United States of America

Industry

Biotechnology

Market Cap

78.3m USD

Dividend Yield

0%

Description

Allakos, Inc. engages in the development of therapeutic antibodies. The company is headquartered in Redwood City, California and currently employs 192 full-time employees. The company went IPO on 2018-07-19. The firm is developing therapeutics, which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory, and proliferative diseases. Its advanced antibodies are lirentelimab (AK002) and AK006. AK002 selectively targets both mast cells and eosinophils, two types of white blood cells that are widely distributed in the body and play a central role in the inflammatory response. The company is developing AK002 for the treatment of eosinophilic esophagitis (EoE), eosinophilic gastritis (EG), eosinophilic duodenitis (EoD), atopic dermatitis, chronic spontaneous urticaria and additional indications. AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. The company also developed a formulation of lirentelimab for subcutaneous (SC) administration. The firm is also developing additional antibodies targeting inhibitory receptors expressed on key disease-driving immune cells.

Contact

CALIFORNIA
Redwood City
975 Island Dr Ste 201
+16505975002.0
www.allakos.com

IPO

2018-07-19

Employees

192

Officers

CEO & Director
Dr. Robert Alexander Ph.D.
President
Dr. Adam L. Tomasi Ph.D.
Chief Financial Officer
Mr. Baird Radford III
Chief Technical Officer
Ms. Mary Cromwell Ph.D.
Chief Medical Officer
Dr. Chin Lee M.D., M.P.H.
Director of Medical Affairs & Data Analytics
Mr. Alan Chang

See Also

Discover More
What is the Intrinsic Value of one ALLK stock?

The intrinsic value of one ALLK stock under the Base Case scenario is 1.0378 USD.

Is ALLK stock undervalued or overvalued?

Compared to the current market price of 0.8766 USD, Allakos Inc is Undervalued by 16%.

Back to Top